IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. today announced that its lead development candidate, RTA 402, has been selected as one of the top 10 most promising cancer drugs in development and available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to executives in the biopharmaceutical industry.
